The role of stent-grafts for prevention and treatment of restenosis

A. T. Kwa, K. K. Yeo, J. R. Laird

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Restenosis rates in the superficial femoral artery remain high in patients treated with balloon angioplasty or bare metal stents. Stent-grafts represent an alternative endovascular treatment modality for these patients. In the US, the only FDA-approved stent-graft for femoral use is the Viabahn endoprosthesis (W.L. Gore, Flagstaff, AZ). The Viabahn is constructed of nitinol and ePTFE and has a proprietary heparin bioactive surface. Stent-grafts have the potential to reduce restenosis by impeding intimal hyperplasia and reducing tissue in-growth; however, the problem of edge restenosis has not been eliminated. Graft thrombosis remains an important mode of stent-graft failure. The Viabahn has been shown in observational studies and randomized trials to be an effective and safe treatment strategy compared to bare self-expanding stents and surgical prosthetic bypass grafts. Patient and appropriate lesion selection remain important in achieving long term patency. In this paper, we review the data surrounding the use of stent-grafts in the SFA to prevent and treat restenosis. Important technical considerations specific to the use of the Viabahn are also discussed.

Original languageEnglish (US)
Pages (from-to)579-589
Number of pages11
JournalJournal of Cardiovascular Surgery
Volume51
Issue number4
StatePublished - Aug 2010

Fingerprint

Stents
Transplants
Therapeutics
Tunica Intima
Balloon Angioplasty
Femoral Artery
Thigh
Hyperplasia
Observational Studies
Heparin
Thrombosis
Metals
Growth

Keywords

  • Coronary restenosis
  • Femoral artery
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Kwa, A. T., Yeo, K. K., & Laird, J. R. (2010). The role of stent-grafts for prevention and treatment of restenosis. Journal of Cardiovascular Surgery, 51(4), 579-589.

The role of stent-grafts for prevention and treatment of restenosis. / Kwa, A. T.; Yeo, K. K.; Laird, J. R.

In: Journal of Cardiovascular Surgery, Vol. 51, No. 4, 08.2010, p. 579-589.

Research output: Contribution to journalArticle

Kwa, AT, Yeo, KK & Laird, JR 2010, 'The role of stent-grafts for prevention and treatment of restenosis', Journal of Cardiovascular Surgery, vol. 51, no. 4, pp. 579-589.
Kwa, A. T. ; Yeo, K. K. ; Laird, J. R. / The role of stent-grafts for prevention and treatment of restenosis. In: Journal of Cardiovascular Surgery. 2010 ; Vol. 51, No. 4. pp. 579-589.
@article{47a11c217e0e435c82ae46c0ee9e4220,
title = "The role of stent-grafts for prevention and treatment of restenosis",
abstract = "Restenosis rates in the superficial femoral artery remain high in patients treated with balloon angioplasty or bare metal stents. Stent-grafts represent an alternative endovascular treatment modality for these patients. In the US, the only FDA-approved stent-graft for femoral use is the Viabahn endoprosthesis (W.L. Gore, Flagstaff, AZ). The Viabahn is constructed of nitinol and ePTFE and has a proprietary heparin bioactive surface. Stent-grafts have the potential to reduce restenosis by impeding intimal hyperplasia and reducing tissue in-growth; however, the problem of edge restenosis has not been eliminated. Graft thrombosis remains an important mode of stent-graft failure. The Viabahn has been shown in observational studies and randomized trials to be an effective and safe treatment strategy compared to bare self-expanding stents and surgical prosthetic bypass grafts. Patient and appropriate lesion selection remain important in achieving long term patency. In this paper, we review the data surrounding the use of stent-grafts in the SFA to prevent and treat restenosis. Important technical considerations specific to the use of the Viabahn are also discussed.",
keywords = "Coronary restenosis, Femoral artery, Thrombosis",
author = "Kwa, {A. T.} and Yeo, {K. K.} and Laird, {J. R.}",
year = "2010",
month = "8",
language = "English (US)",
volume = "51",
pages = "579--589",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - The role of stent-grafts for prevention and treatment of restenosis

AU - Kwa, A. T.

AU - Yeo, K. K.

AU - Laird, J. R.

PY - 2010/8

Y1 - 2010/8

N2 - Restenosis rates in the superficial femoral artery remain high in patients treated with balloon angioplasty or bare metal stents. Stent-grafts represent an alternative endovascular treatment modality for these patients. In the US, the only FDA-approved stent-graft for femoral use is the Viabahn endoprosthesis (W.L. Gore, Flagstaff, AZ). The Viabahn is constructed of nitinol and ePTFE and has a proprietary heparin bioactive surface. Stent-grafts have the potential to reduce restenosis by impeding intimal hyperplasia and reducing tissue in-growth; however, the problem of edge restenosis has not been eliminated. Graft thrombosis remains an important mode of stent-graft failure. The Viabahn has been shown in observational studies and randomized trials to be an effective and safe treatment strategy compared to bare self-expanding stents and surgical prosthetic bypass grafts. Patient and appropriate lesion selection remain important in achieving long term patency. In this paper, we review the data surrounding the use of stent-grafts in the SFA to prevent and treat restenosis. Important technical considerations specific to the use of the Viabahn are also discussed.

AB - Restenosis rates in the superficial femoral artery remain high in patients treated with balloon angioplasty or bare metal stents. Stent-grafts represent an alternative endovascular treatment modality for these patients. In the US, the only FDA-approved stent-graft for femoral use is the Viabahn endoprosthesis (W.L. Gore, Flagstaff, AZ). The Viabahn is constructed of nitinol and ePTFE and has a proprietary heparin bioactive surface. Stent-grafts have the potential to reduce restenosis by impeding intimal hyperplasia and reducing tissue in-growth; however, the problem of edge restenosis has not been eliminated. Graft thrombosis remains an important mode of stent-graft failure. The Viabahn has been shown in observational studies and randomized trials to be an effective and safe treatment strategy compared to bare self-expanding stents and surgical prosthetic bypass grafts. Patient and appropriate lesion selection remain important in achieving long term patency. In this paper, we review the data surrounding the use of stent-grafts in the SFA to prevent and treat restenosis. Important technical considerations specific to the use of the Viabahn are also discussed.

KW - Coronary restenosis

KW - Femoral artery

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=78649241789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649241789&partnerID=8YFLogxK

M3 - Article

C2 - 20671643

AN - SCOPUS:78649241789

VL - 51

SP - 579

EP - 589

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - 4

ER -